Aberrant Expression of Long Non-Coding RNAs (lncrnas) is Involved in Brain Glioma Development
Yi Ding,Xinfa Wang,Junchen Pan,Minjun Ji,Zhengxiang Luo,Penglai Zhao,Yansong Zhang,Gang Wang
DOI: https://doi.org/10.5114/aoms.2020.91290
2020-01-01
Archives of Medical Science
Abstract:Introduction Aberrant expression of long non-coding RNAs (lncRNAs) has been implicated in various diseases, including cancer. However, little is known about lncRNAs in human brain gliomas. Material and methods We examined lncRNA profiles from three glioma specimens using lncRNA expression profiling microarrays. Quantitative real-time RT-PCR was used to analyze the differential expression of raw intensities of lncRNA expression in glioma and peritumoral tissues. Results We found 4858 lncRNAs to be differentially expressed between tumor tissue and peritumoral tissue. Of these, 2845 lncRNAs were up-regulated (fold change > 3.0) and 2013 were down-regulated (fold change < 1/3). A total of 4084 messenger RNAs were also differentially expressed, including 2280 up-regulated transcripts (fold change > 3.0) and 1804 that were down-regulated (fold change < 1/3). Consistent with the microarray data, qPCR confirmed differential expression of these 6 lncRNAs (ak125809, ak098473, uc002ehu.1, bc043564, NR_027322, and uc003qmb.2) between tumor and peritumoral tissue. We next established co-expression networks of differentially expressed lncRNAs and mRNAs. Many mRNAs, such as LOC729991, NUDCD1, SHC3, PDGFA, and MDM2, and lncRNAs, such as ENST00000425922, ENST00000455568, uc002ukz.1, ENST00000502715, and NR_027873, have been shown to play important roles in glioma development. Consistent with this, pathway analysis revealed that “GLIOMA” (KEGG Pathway ID: hsa05214) was significantly enriched in tumor tissue. Conclusions Our data suggest that altered expression of lncRNAs may be a critical determinant of tumorigenesis in glioma patients.